Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 24, 2021, Roderick Wong, M.D., resigned from the Board of Directors
(the "Board") of Avidity Biosciences, Inc. (the "Company"), effective August 25,
2021. Dr. Wong advised the Company that his decision to resign was not the
result of any disagreement with the Company or its management on any matter
relating to the Company's operations, policies or practices.
Additionally, on August 25, 2021, upon the recommendation of the Nominating and
Corporate Governance Committee of the Board, and pursuant to the amended and
restated bylaws of the Company, the Board appointed Eric Mosbrooker to fill the
vacancy created by such resignation. Mr. Mosbrooker will serve as a Class II
director, with an initial term expiring at the Company's 2022 annual meeting of
stockholders. In connection with such Board appointment, effective as of
August 25, 2021, Mr. Mosbrooker was appointed to the Compensation Committee of
the Board. In addition, Tamar Thompson was appointed to the Nominating and
Corporate Governance Committee of the Board.
Since March 2021, Mr. Mosbrooker has served as Chief Operations Officer of
Cognoa, Inc. Previously, Mr. Mosbrooker has served as Senior Vice President and
Chief Commercial Officer of Audentes Therapeutics, Inc. from January 2019 to
January 2021. From August 2018 to December 2018, Mr. Mosbrooker served first as
Chief Commercial Officer and later as Chief Operating Officer at Origin
Biosciences, a subsidiary of BridgeBio Pharma LLC focused on developing a rare
pediatric metabolic disorder treatment. From November 2016 to April 2018,
following its acquisition of Raptor Pharmaceuticals Corp, he served at Horizon
Pharma plc as Group Vice President and GM and later as Senior Vice President and
GM. Prior to the acquisition by Horizon Pharma, Mr. Mosbrooker served in various
positions at Raptor Pharmaceuticals from November 2012, including Senior Vice
President of Americas & Asia Pacific from March 2016 to November 2016. Prior to
Raptor, Mr. Mosbrooker served as commercial operations and market access lead
for STRENSIQ® at Alexion Pharmaceuticals, Inc. and Enobia Pharma, Inc. He has
held various commercial operational roles at Onyx Pharmaceuticals, Inc., Jazz
Pharmaceuticals Inc., Chiron Corporation (now Novartis) and Millennium
Pharmaceuticals, Inc. He has experience in management, healthcare and technology
consulting at IBM, Teltech Resource Network Corporation and Kohler Company.
Mr. Mosbrooker earned his B.S. in Industrial Engineering from the University of
Wisconsin, Madison.
Pursuant to the Company's non-employee director compensation program,
Mr. Mosbrooker was granted on the date of his appointment options to purchase
30,000 shares of the Company's common stock, which vest in substantially equal
monthly installments over the three years following his appointment to the
Board. Mr. Mosbrooker will receive cash compensation for his service on the
Board in accordance with the Company's non-employee director compensation
program, as such program may be amended from time to time. Mr. Mosbrooker has
also entered into the Company's standard form of Indemnification Agreement, the
form of which was filed as Exhibit 10.11 to the Company's Annual Report on Form
10-K, filed with the SEC on March 15, 2021.
There is no arrangement or understanding between Mr. Mosbrooker and any other
person pursuant to which Mr. Mosbrooker was appointed as a director.
Mr. Mosbrooker is not a party to any transaction that would require disclosure
under Item 404(a) of Regulation S-K promulgated under the Securities Act of
1933, as amended. The Board has determined that Mr. Mosbrooker is an independent
director in accordance with the listing requirements of the Nasdaq Global
Market.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
AVIDITY BIOSCIENCES, INC. 
